Tyra Biosciences, Inc. has announced the commencement of dosing for the first patient in its Phase 2 SURF302 clinical trial, evaluating the efficacy and safety of TYRA-300 in patients with low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). TYRA-300 is currently the only orally administered investigational agent in clinical development for this condition. The trial aims to enroll up to 90 participants across multiple sites in the United States. Participants will receive either 50 mg or 60 mg of TYRA-300 once daily. The study's primary endpoint is the complete response rate at three months, with initial data expected in the first half of 2026. Secondary endpoints include recurrence metrics and safety evaluations. Results from the trial have not yet been presented.